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Renal vascular effects of antihypertensive therapy in uninephrecto-
mized SHR. Serial determinations of protein excretion rate and systolic
blood pressure (SBP) were made in spontaneously hypertensive rats
(SHR) uninephrectomized (UNX) at six weeks of age and given tap
water (CON), or water with hydrochiorthiazide, hydralazine and reser-
pine (HHR), captopril (CAP) or enalapril (ENP). Compared to CON,
significant hypertension was prevented, kidney weight was lower and
there was less proteinuria in HHR, CAP and ENP rats followed for 30
weeks after UNX. Morphologic studies of these four groups revealed
that antihypertensive therapy reduced the incidence of glomerular
sclerosis in UNX SHR by 50%. Despite complete absence of systemic
hypertension, there was striking medial thickening of lobular arteries
and arterioles of rats given the angiotensin converting enzyme (ACE)
inhibitor, captopril, These vascular abnormalities were present to a
lesser degree in rats given ENP, but were entirely absent in untreated
animals or in those ingesting the HHR combination. Micropuncture
studies performed five weeks after UNX in four additional groups of
CON, HHR, CAP and ENP rats revealed that glomerular capillary
pressure was elevated in CON and reduced by all three drug regimens.
These studies support the hypothesis that glomerular capillary hyper-
tension and/or nephron hypertrophy predispose to glomerular injury in
this model of hypertension and reduced renal mass. ACE inhibitors and
HHR are equivalent in their ability to prevent glomerular hypertension
and damage in these rats, but the former, and in particular captopril,
produce abnormalities of cortical vessels via a mechanism not depen-
dent on the presence of systemic hypertension.
The remnant kidney rat [1], desoxycorticosterone-salt treated
rat (DOC-SALT) [21 and uninephrectomized spontaneously
hypertensive rat (SHR) [3] are related models of hypertension
characterized by reduction in functioning renal mass, compen-
satory hypertrophy of remaining renal tissue, and elevation in
systemic and glomerular capillary (Gc) hydraulic pressure.
Despite irregular effects on mean arterial pressure (A),dietary
protein restriction reduces GC and prevents nephrosclerosis
and proteinuria in all three models [1—31. This suggests that
glomerular capillary hypertension is not only associated with,
but pathogenically related to glomerular injury in this setting.
The therapeutic implications of this latter observation have
been recognized, and a number of clinical trials of protein
restriction [4—6] in patients with mild to moderate renal insuf-
ficiency support the notion that reducing protein intake pre-
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serves filtration capacity in man. Unfortunately and discussed
ill detail elsewhere [7], owing primarily to difficulties with
patient compliance with required diets, widespread application
of protein restriction to the treatment of renal disease in humans
may not be practical.
If glomerular injury in hypertension results from increased
hydraulic pressure within the glomerular capillary, then phar-
macologic reduction of systemic pressure might also cause
glomerular pressure to decline and protect the kidney from
injury. In accord with this hypothesis, recent studies in the
remnant kidney model [8] indicate that the angiotensin convert-
ing enzyme (ACE) inhibitor, enalapril, may be as effective as
dietary protein restriction in lowering glomerular pressure and
preventing hypertensive nephrosclerosis. It has also been sug-
gested that, since the renal circulatory effects of the various
antihypertensive agents may differ significantly [9], other drugs
with equivalent effects on systemic blood pressure may not
reduce glomerular pressure or prevent hypertensive glomerular
injury [10, 111. As we have previously provided evidence [3]
that glomerular damage is hemodynamically mediated in uni-
nephrectomized SHR, we decided to compare the effects of two
ACE inhibitors, captopril and enalapril, with the combination of
hydrochiorthiazide, hydralazine and reserpine on glomerular
perfusion and vascular injury in this experimental model.
Methods
Description of groups
Studies were performed in eight groups of male SHR (Ta-
conic Farms, New York, USA). All rats underwent right
nephrectomy at six weeks of age and were fed standard rat
chow (Purina, Richmond, Indiana, USA) containing 24% pro-
tein by weight. Initial studies were performed in four groups of
rats sacrificed at 36 weeks of age. CON rats (N 6) were
untreated and given tap water for drinking. Rats in the three
remaining groups received antihypertensive therapy added to
their drinking solution in the form of: hydrochlorthiazide 200
mg/liter, hydralazine 500 mg/liter and reserpine 4 mg/liter
(CIBA) (HHR, N = 6); captopril (Squibb & Sons) 300 mg/liter
(CAP, N = 6) or enalapril (Merck, Sharp & Dohme) 150 mg/
liter (ENP, N = 6). Drug doses were derived from preliminary
studies in UNX SHR in our laboratory (data not shown) in
which the lowest dose of each agent associated with mainte-
nance, over time, of normal or nearly normal systolic blood
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pressure was identified. Fresh drinking solution was supplied
daily. Four additional, identically treated groups of CON (N =
15), HHR(N = 12), CAP(N = 11) and ENP(N = 10) were used
for micropuncture studies of glomerular hemodynamics per-
formed at 11 weeks of age, five weeks after nephrectomy.
Awake protein excretion and systolic blood pressure
determinations
Animals followed for 36 weeks were periodically placed in
metabolic cages and 24-hour urine collections were made for
determination of protein excretion rate. Urinary protein con-
centration was measured by precipitation with 3% sulfosalicylic
acid. Turbity was then determined by measuring absorbance at
a wavelength of 595 m using a Coleman Junior II spectropho-
tometer.
Awake systolic blood pressure was also periodically mea-
sured using a photoelectric tail cuff device (Model 29, I.I.T.C.,
Inc. Woodland Hills, California, USA). This device requires
minimal warming of the rat (usually <15 mm) prior to blood
pressure determination and only brief residence in a plastic
restraining cage. Rats were quickly trained to accept this
procedure and to sit quietly in the restraining device. For each
animal, the systolic blood pressure recorded for any given time
represents the mean of four to six pressure recordings obtained
at a single sitting.
Morphologic studies
At 36 weeks of age, rats were anesthetized with Inactin (100
mg/kg body weight, i.p.). A polyethylene catheter (PE5O) was
placed in the femoral artery and mean arterial pressure directly
measured by a Statham P23B pressure transducer connected to
a Grass Recorder (Model 7A, Grass Instruments, Quincy,
Massachusetts, USA). The abdomen was then opened via a
midline incision. The hepatic and superior mesenteric arteries
were ligated and a perfusion catheter inserted into the abdom-
inal aorta below the origin of the renal arteries. The aorta was
then occluded above the level of the renal arteries, and the
kidney was fixed by perfusion for five minutes at the measured
arterial pressure with 1.25% glutaraldehyde in 0.1 M cacodylate
buffer (pH 7.4). The kidney was then excised and weighed. Two
coronal slices of each kidney, which included one pole and the
middle portion, were processed routinely for light microscopy
through paraffin embedding. Sections 3 thick were stained
with hematoxylin/eosin (H & E) and periodic acid-Schiff. Se-
lected silver methenamine stained sections were also examined.
The incidence of glomerular sclerosis was quantitatively as-
sessed in a blinded fashion by one observer (H.F.) using H and
E sections. An average of 203 glomeruli (range 167 to 230) were
examined in each rat. The percentage of glomeruli with glomer-
ular sclerosis was calculated for each animal by dividing the
number of abnormal glomeruli by the total number examined in
that animal. Vascular and tubulointerstitial abnormalities were
also assessed in a blinded fashion but in a nonquantitative
manner.
Cortical micropuncture studies
Micropuncture studies were performed in rats at 11 weeks of
age. Rats were anesthetized with mactin (100 mg/kg body
weight, i.p.) and prepared in the standard fashion for micro-
puncture [12]. Briefly, a tracheostomy was performed and
polyethylene catheters placed in the left and right jugular veins,
left femoral artery and ureter for infusion of solutions and
collection of samples. The kidney was exposed via a left
subcostal incision, placed on a lucite holder, and illuminated
with a fiberoptic light. When the surgical preparation was
complete and to compensate for the loss of plasma associated
with anesthesia and surgery, all rats received intravenous
infusions of a volume of heparinized isoncotic rat plasma equal
to 10 ml per kilogram body weight at a rate of 0.1 ml per minute,
followed by sustaining infusions of plasma at approximately 0.5
ml per hour, adjusted to maintain hematocrit stable at baseline
values. In addition, all rats received a 0.5 ml intravenous bolus
of [3H] methoxyinulin (120 Ci/ml; I.C.N. Pharmaceuticals,
Irvine, California, USA) in normal saline followed by a sustain-
ing infusion of inulin at a rate of 0.5 ml per hour. Micropuncture
measurements were instituted 45 to 60 minutes after the com-
pletion of surgery and the start of the inulin infusion.
Timed collections of proximal tubule fluid were obtained by
micropuncture for determination of inulin content by liquid
scintillation counting. Plasma and urine inulin concentrations
were similarly determined and these measurements used to
calculate SNGFR and whole kidney GFR by standard fomulas
[12]. Efferent arterial blood samples were obtained for measure-
ment of total protein concentration by the method of Viets et al
[13]. Hydraulic pressure in cortical tubules and efferent arte-
rioles was measured using the servo-null micropipette tech-
nique [12]. Since SHR do not possess glomeruli on the kidney
surface, mean glomerular capillary hydraulic pressure was
estimated by the stop-flow technique of Allison, Lipham and
Gottschalk [14], which has been reported to accurately assess
glomerular pressure in this strain [15, 16]. Calculation of the
determinants of glomerular ultrafiltration and vascular resis-
tances were made using standard formulas as set out by Baylis
et al [12].
Analysis of data
Statistical analysis of morphologic data was performed by
Kruskal-Wallis Test (Chi-Square Approximation) [17] and func-
tional data by one-way analysis of variance followed by com-
putation of modified t values and multiple pairwise comparisons
according to the method of Bonferroni [18]. Statistical signifi-
cance was defined as P < 0.05. Data are reported as Mean SE.
Results
Whole animal studies
Rats in all four groups gained weight during the 30 weeks
from time of nephrectomy to time of sacrifice. Weight increases
were greatest during the initial part of the study and body
weight tended to plateau at 20 to 24 weeks of age in all groups.
In general body weight in untreated SHR exceeded that seen in
treated rats by 30 to 60 g throughout the course of the study. At
the time of sacrifice, body weight in CON averaged 398 10 g,
a value significantly greater than the corresponding values of
332 7 in HHR, 348 13 in CAP, and 352 10 in ENP.
Differences in perfused kidney weight were also noted at the
time of sacrifice. Wet weight averaged 3.120 0.099 g in CON,
a value significantly greater than that of 2.558 0.099 in HHR,
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Fig. 1. Awake systolic blood pressure. Mean systolic blood pressure(SBP) measured time of nephrectomy to time of sacrifice in awake rats
followed for 30 weeks is plotted. * indicates a value In CON which is
significantly greater P < 0.05 than that observed in HHR, CAP, or
ENP. ** indicates a value in ENP which is significantly greater P < 0.05
than that in HHR or CAP. Symbols are: (O—O) CON, (• •)
CAP, (A----) HHR, (A A) ENP.
2.385 0.099 in CAP and numerically greater than that of 2.708
0.154 in ENP rats.
Figure 1 displays mean values for systolic blood pressure
measured in these rats. Although not plotted, the average
coefficients of variation were 7%, 17%, 14%, and 8% for CON,
HHR, CAP and ENP, respectively. SBP was already signifi-
cantly elevated in CON rats at eight weeks of age, to 179 7
mm Hg, and rose to 204 8 by 12 weeks. This degree of blood
pressure elevation was sustained up to the time of sacrifice. In
contrast, significant hypertension was completely prevented in
the HHR and CAP groups where SBP never exceeded, and was
generally less than, 136 mm Hg. A small but significant eleva-
tion in blood pressure was observed in ENP, as SBP reached
and was sustained at 155 5 mm Hg from 24 to 32 weeks of age.
This value was significantly greater than that observed in HHR
and CAP (104 10 and 119 8, respectively at 32 weeks), but
still less than that observed in CON animals (203 9). The
explanation for the different blood pressure response to ENP
versus CAP is uncertain, but probably did not result from
between group differences in water intake, as urine volumes
were similar in these two groups throughout the study (data not
shown). Mean arterial pressure directly measured in anesthe-
tized rats at the time of sacrifice was also increased in CON rats
to 214 12 mm Hg, a value which significantly exceeded that of
124 4 in HHR, 84 5 in CAP, and 129 3 in ENP rats.
Figure 2 shows 24-hour protein excretion with time in these
four groups of rats. Coefficients of variation averaged 36% in
CON, 33% in group HHR, 27% in CAP and 26% in ENP.
Protein excretion tended to increase with time in all four
groups; however, by 32 weeks of age proteinuria was and
remained significantly greater in CON rats than in any of the
other groups, among which protein excretion rates were not
statistically different.
Morphologic studies
Glomerular sclerosis, defined as global or segmental collapse
or obliteration of glomerular capillaries associated with in-
Age, weeks
Fig. 2. Protein excretion rates. Mean 24-hour protein excretion rates
from time of nephrectomy to sacrifice in CON (O—O), HHR (----),
CAP (• •) and ENP (A A) groups are plotted. * indicates a value
measured in untreated, CON rats which is significantly greater than that
observed in HHR, CAP and ENP.
creased basement membrane material, capsular adhesion, dila-
tation of Bowman's space and fibrosis of Bowman's capsule
(Fig. 3), occurred in all groups and was most prominent in deep
glomeruli, however, occasional sclerotic glomeruli were ob-
served in the outer cortex. As summarized in Figure 4, the
incidence of sclerotic glomeruli was reduced by approximately
50% in the treated animals. There was no difference in the
percentage of sclerotic glomeruli among the three treated
groups.
In contrast to glomerular lesions, significant differences in
vascular morphology were observed among the treated groups.
In the captopril treated group, both the interlobular arteries,
which arise as right angled branches from the arcuate arteries
[191, and the afferent arterioles, which arise as acute angled
branches from the interlobular arteries, showed striking medial
thickening (Figs. 5B,D). In individual animals, this change was
irregularly distributed among interlobular arteries and arte-
rioles, inasmuch as less than 25% of vascular cross sections
showed the abnormality. This change affected mainly preglo-
merular vessels (Fig. SB), however, in occasional glomeruli
which were cut through the vascular pole such that both
afferent and efferent arterioles could be recognized, both
showed medial thickening (Fig. 5D). Medial thickening was
slight or equivocal in enalapril treated animals, and was not
observed in the HHR or untreated groups.
Tubulointerstitial damage correlated with glomerular rather
than vascular changes, and was marked in juxtamedullary
zones of control animals and negligible in the treated groups.
Micropuncture studies of glomerular hemodynamics
Mean values for body weight; Hct; A; whole kidney and
single nephron (SN)GFR; and the pressures, flows and resis-
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Fig. 3. A. Nonscierotic glomerulus (from HHR rat). x600 B. Sclerotic glomerulus (from HHR rat). Note increased basement membrane material
in the tuft, adhesion to Bowman's capsule and widened Bowman's space. x600.
tances governing glomerular ultrafiltration for CON, HHR,
CAP and ENP rats at 11 weeks of age are given in Table 1. As
was the case at 36 weeks, body weight at 11 weeks was
approximately 10% less in rats on antihypertensive therapy as
compared with the mean value observed in CON. Mean arterial
pressure directly measured at the time of micropuncture corre-
lated well with awake systolic pressures measured by the tail
cuff technique and revealed that all three antihypertensive
regimens effectively prevented the systemic hypertension in
UNX SHR. Whole kidney and single nephron filtration rates
were similar in all four groups and were mildly elevated as
compared with values previously observed in intact SHR in our
laboratory [3].
Importantly, despite this similarity in filtration rates, GCand
were significantly reduced, by 6 mm Hg in rats given HHR
or ENP and by 8 mm Hg in the CAP treated group compared to
untreated CON SHR. Calculation of pre- and post-glomerular
resistance revealed that, associated with the reduction in AP
observed in rats on antihypertensive therapy, RA declined by
59%, 76% and 49% in HHR, CAP and ENP, respectively, from
the mean value of 2.51 0.21 dyne . s cm5 x 10l calculated
for CON rats. Assuming that postglomerular resistance and
glomerular blood flow remained constant, this reduction in RA
would have resulted in near constancy of P6 and is therefore
consistent with a myogenic response of the preglomerular
vasculature to reduced perfusion pressure. However, drug
therapy also tended to cause RE to decline, significantly in HHR
and CAP rats and numerically in ENP animals, and it was this
reduction which was largely responsible for the observed
reduction in ic in treated rats.
Discussion
In a previous study [3], we demonstrated that UNX led to
increases in glomerular flow and pressure in excess of values
observed in superficial nephrons of intact SHR, and that this
hemodynamic alteration was associated with more rapid and
widespread appearance of glomerular injury, so that both
superficial and deep nephrons displayed structural abnormali-
ties. Although intact animals were not examined in the present
study, the pattern of glomerular perfusion observed in un-
treated UNX SHR was similar to that which we reported
previously [3], the most prominent abnormality being an in-
crease in 1'GC
The present study was designed to examine the effect of
antihypertensive drug therapy on glomerular perfusion and
injury in this model of hypertension and moderate renal insuf-
ficiency. Most important, our data continue to support the
hypothesis that glomerular capillary hypertension predisposes
to glomerular injury. Thus, P was elevated in superficial
nephrons of UNX SHR prior to the appearance of proteinuric
or morphologic evidence of glomerular damage, and therapy, in
this case administration of either HHR or ACE inhibitors,
which reduced GC lessened the incidence of glomerular scle-
rosis in these rats. The observation that glomerular injury was
reduced in HHR and CAP treated animals despite the fact that
QA was not significantly altered in these rats suggests that
increased glomerular pressure is the hemodynamic alteration
which is pathogenically related to glomerular sclerosis. Further-
more, as single nephron and whole kidney filtration rates were
not different in treated and untreated rats, it appears that
glomerular injury could be partly prevented despite the persis-
tence of suDranormal filtration rates.
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Fig. 4. Effect of therapy on the incidence of glomerular sclerosis. The
mean (±sE) percentage of sclerotic glomeruli in rats sacrificed at 36
weeks of age. * indicatesP < 0.05 in CON versus HHR, CAP and ENP.
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Table 1. Micropuncture data
Group
Weight
g
HCT
%
AP oc T PE hP CA CE
mm Hg g/100 ml
5 263 3 46 1 155 2 67 1 13 0.4 15 0.3 54 1 5.8 0.03 9.7 0.2
CON (15) (15) (15) (15) (15) (15) (15) (15) (14)
6 228 5 44 1 108 2 61 1 14 0.4 17 1 48 1 5.9 0.1 9.0 0.3
HHR (12) (12) (12) (12) (12) (12) (12) (12) (12)
7 237 2 43 1 88 3 59 2 14 0.4 16 1 45 2 5.7 0.05 8.8 0.2
CAP (11) (11) (11) (11) (11) (11) (II) (11) (11)
8 244±4 44±1 106±3 61±2 13±0.5 16±1 48±2 5.8±0.1 9.5±0.2
ENP (10) (10) (10) (10) (10) (10) (10) (10) (10)
P
5 vs. 6 <0.05 NS <0.05 <0.05 NS NS <0.05 NS NS
5 vs. 7 <0.05 <0.05 <0.05 <0.05 NS NS <0.05 NS NS
5 vs. 8 <0.05 NS <0.05 <0.05 NS NS <0.05 NS NS
6 vs. 7 NS NS <0.05 NS NS NS NS NS NS
6 vs. 8 <0.05 NS NS NS NS NS NS NS NS
7 vs. 8 NS NS <0.05 NS NS NS NS NS NS
All data are means SE. (N) Indicates number of animals in which values were obtained; NS = not significantly different; see Appendix for
explanation of other abbreviations.
Fig. 5. A. Large (top left) and small (arrows) interlobular arteries from an untreated SHR (CON), As compared to SHR treated with captopril
(B,D) the interlobular arteries have larger lumens and thinner walls. x600, B. Captopril treated SHR. Small interlobular arteries (arrows) show
reduced luminal size and thicker walls in comparison with untreated SHR (A). x240. The inset shows the same vessels; note the vacuolation of
smooth muscle cell (arrowhead), its nature is uncertain. x600. C. A glomerulus from an untreated SHR (CON) sectioned through the vascular pole
and showing the afferent and efferent arterioles, which cannot be distinguished one from the other. x600. D. As compared to untreated SHR (C)
arterioles from a CAP rat have much thicker walls. x600.
Several points need to be addressed concerning the reduc- exactly equivalent reductions in blood pressure were not
tions in systemic and glomerular pressure observed in treated achieved in all groups. However, it should be remembered that
rats in our study. First, it might appear that comparisons of the purpose of our study was to examine the effects of reduc-
injury among our treated groups were not warranted, since tions in glomerular pressure on glomerular injury. In this
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Table 1. Continued
H
mm Hg HE/AP SNFF
GFR
mi/mm
SNGFR QA K
ni/s mm Hg
RA RE RT
ni/mm dyne s cm5 >< 1010
44 2 0.83 0.02 0.39 0.01 1.46 0.12 57.6 4.5 136 11 0.044 0.003 2.51 0.21 1.82 0.15 4.34 0.34
(14) (14) (14) (11) (11) (10) (10) (10) (10) (10)
38 2 0.82 0.05 0.35 0.02 1.59 0.12 59.1 4.3 183 28 0.057 0.006 1.03 0.10 1.23 0.17 2.25 0.26
(12) (12) (12) (II) (11) (II) (10) (II) (11) (11)
37 2 0.83 0.02 0.36 0.02 1.41 0.11 61.2 6.1 176 21 0.063 0.008 0.61 0.10 1.11 0.13 1.71 0.20
(ii) (11) (ii) (11) (11) (Ii) (II) (11) (11) (Ii)
42 2 0.88 0.06 0.39 0.02 1.69 0.09 49.3 3.7 131 13 0.048 0.005 1.29 0.14 1.54 0.10 2.83 0.21
(10) (10) (10) (10) (10) (10) (10) (10) (10) (10)
NS NS NS NS NS NS NS <0.05 <0.05 <0.05
NS NS NS NS NS NS NS <0.05 <0.05 <0.05
NS NS NS NS NS NS NS <0.05 NS <0.05
NS NS NS NS NS NS NS NS NS NS
NS NS NS NS NS NS NS NS NS NS
NS NS NS NS NS NS NS <0.05 NS <0.05
regard, HHR, CAP and ENP caused similar declines in GC'
and these were associated with essentially equivalent protec-
tion from glomerular injury in the three treated groups. A
second concern was that, since systemic blood pressure at the
time of micropuncture was lower in CAP than in HHR or ENP
rats, GC might have declined in the CAP group because AIhad
fallen below the limits of autoregulation. However, despite the
lower mean value for A, GFR and QA were similar among the
groups, suggesting that CAP rats were still operating within the
autoregulatory range. Furthermore, calculations indicate that
the observed autoregulatory decline in RA in the CAP group
was sufficient in magnitude to offset the fall in A1and maintain
c constant. Actually, the reduction in GC in this group
resulted from a decline in RE, a response consistent with a
direct vascular effect of the drug on the efferent arteriole.
Finally, it might be argued that the 6 to 8 mm Hg reduction in
GC which we observed in treated rats was small and therefore
unlikely to account for the preservation of glomerular architec-
ture which accompanied chronic drug administration. In fact,
GC was still somewhat elevated in treated rats when compared
to values we have reported [3] in intact SHR. Furthermore,
glomerular damage was not as effectively prevented by antihy-
pertensive therapy as it was by protein restriction in our
previous study. This latter maneuver is associated with com-
plete normalization of PGC in this model [3]. It is attractive to
speculate that had greater reduction in P0 been achieved,
injury might have been more completely prevented.
Nevertheless, it is possible that antihypertensive therapy
lessened glomerular injury by some mechanism other than a
direct effect of these agents on resistance vessels tending to
reduce GC• One possibility, suggested by the fact that rats on
therapy weighed less than untreated animals, is that food intake
was lower in treated rats and that relative protein restriction
accounted for the observed reduction in P0 and injury in
groups 2 to 4. An analysis of the arteriolar resistance data in this
and our previous study, where protein restriction was specifi-
cally examined as a therapeutic modality, suggests that this
explanation is unlikely. As illustrated in Figure 6, in protein
restricted rats, Pc declines because preglomerular resistance
increases dramatically. Of note, RE is also increased. In con-
Fig. 6. Effect of a low protein diet versus antihypertensive therapy on
arteriolar resistance in UNX SHR. Resistance is expressed as percent
difference from mean values observed in untreated rats. Values for low
protein diet are recalculated from reference 3. Low protein (low prot)
rats consumed a 6% protein diet from time to nephrectomy to time of
study. Symbols are: (D) low protein, () HHR, (LI) CAP, (0) ENP.
trast, the decline in P0 observed in rats receiving antihyper-
tensive drugs results primarily from a drug induced reduction in
RE, with RA also tending to decline. Thus, although both
protein restriction and drug therapy are associated with reduc-
tion in glomerular pressure, this reduction results from direc-
tionally opposite changes in arteriolar resistance.
Alternatively, protein/calorie restriction might have lessened
glomerular injury by some mechanism unrelated to alterations
in glomerular perfusion. One independent risk factor for gb-
merular injury which has recently been identified in SHR [20]
and in the remnant kidney model [21, 22] is renal hypertrophy.
For example, we reported [20] that dietary salt restriction
reduced kidney growth and prevented glomerular injury in
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UNX SHR, without reducing glomerular capillary pressure. In
fact, kidney weight was significantly reduced in HHR and CAP
treated rats in our study and this reduction might be related to
the protective effect of drug therapy. It is possible that the
lower kidney weights we observed in treated rats resulted from
decreased food intake in those groups. Alternatively, reduced
kidney size might have resulted from a direct action of the drugs
to limit hypertrophy. This latter hypothesis is supported by the
observation, in the salt restriction study described above [201,
that glomerular injury was not prevented by a degree of food
restriction which resulted in modest growth retardation in
otherwise untreated UNX SHR.
Although both ACE inhibitors and the HHR combination
reduced glomerular pressure and injury in UNX SHR, previous
reports suggest that these agents may not always be equal in
their ability to prevent hemodynamically-mediated glomerular
injury. For example, HHR reduced systemic and intrarenal
pressure and lessened kidney damage in a hypertensive model
of nephrotoxic serum nephritis (NSN) [23]. However, despite
normalization of systemic blood pressure, it failed to reduce
glomerular pressure or injury in either the DOC-SALT [11] or
remnant kidney models [10] of hypertension. In the remnant
model, enalapril lessens intrarenal pressure and glomerular
pathology. The explanation for the finding that HHR lowers
GC in UNX SHR but not in DOC-SALT or remnant rats is
uncertain, but some insight can be gained by an analysis of
Figure 7, which compares the changes in afferent and efferent
arteriolar resistance induced by administration of this drug
combination to UNX SHR, remnant kidney and DOC-SALT
rats, the three forms of experimental hypertension for which
these values are available. In both the remnant and DOC-SALT
models, remained elevated because HHR caused a marked
decline in RA to a value so low that glomerular pressure
remained elevated even though systemic pressure was normal.
RE remained constant or even increased in these models. In
UNX SHR, HHR caused not only RA but also RE to decrease.
In this case, the fall in efferent resistance largely accounts for
the fall in glomerular pressure. In fact, the glomerular effects of
HHR exactly mimic those of the ACE inhibitors in this model.
At present, the explanation for the different response of the
efferent circulation to this drug combination in SHR is un-
known, but may relate to the higher baseline arteriolar resis-
tances in SHR as compared to remnant or DOC-SALT rats, or
to the larger drug dose used in the current study.
An unexpected result of our experiment was the finding that,
although glomerular capillary injury was ameliorated, abnor-
malities of cortical vessels were found in rats given ACE
inhibitors. Medial thickening, presumably the result of smooth
muscle hypertrophy and/or hyperplasia, was widespread in
preglomerular vessels and may also have affected efferent
arterioles in rats on CAP. Vascular lesions were less prominent
in ENP, however, this finding is difficult to interpret in light of
the lesser decline in mean arterial pressure observed in this
group. Even for the CAP group, the distribution of these
abnormalities within the renal vasculature could not be pre-
cisely assessed by the routine histologic methods which we
employed. In histologic sections, well oriented cross sections of
affected vessels are required to assess medial thickening with
luminal narrowing and this precludes examination of long
stretches of the vessel. It may be that the abnormalities are
segmental, with dilatation proximal to and between segmental
constrictions. Alternatively, constrictions may be uniform and
tapering. The irregular distribution of abnormal vessels also
precluded precise measurements of wall thickness in these rats.
Thus, since only one-third or less of the vessels in a given
section were abnormal, determination of mean wall thickness
would have tended to "dilute" the differences between groups.
Nevertheless, our finding that approximately one-fourth of
properly oriented vascular cross sections were abnormal in rats
given CAP suggests that the lesion was fairly widespread in this
group.
The vascular abnormalities which we have noted are similar
to those observed in human hypertension. This was unexpected
since they were not present in untreated hypertensive animals
and since ACE inhibition was begun prior to the onset of
hypertension in our study, so that animals so treated never had
increased systemic arterial pressure. Thus, one must conclude
that the vascular abnormalities represent an effect of the drug
per se. Of note, captopril has previously been observed to
promote vascular smooth muscle hypertrophy in the renal
cortex [24]. In that study, the effect was dose dependent and
evident in some rats ingesting as little as 30 mg/kg of drug per
day.
The mechanism by which CAP and ENP promote smooth
muscle hypertrophy was not addressed by our study, however,
possible explanations relate to the potential hemodynamic,
toxic and/or hormonal effects of these agents. For example, if
hypertrophy results from increased hydraulic pressure or wall
tension within blood vessels, one possibility is that the predom-
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Fig. 7. Effect of HHR on arteriolar resistance in 3 models of hyper-
tension with reduced renal mass. Values for remnant kidney rats are
recalculated from reference 10, DOC-SALT rats from reference 11.
Symbols are: (D) remnant, (U) DOC-SALT, () SHR.
Dworkin et at: Antihypertensive therapy in SHR 797
inant site of preglomerular vascular resistance was shifted
downstream in rats given CAP or ENP. Total preglomerular
resistance might not decrease and GC not increase, however
more distal vessels, such as the afferent arteriole might be
exposed to higher distending pressures. This hypothesis is
consistent with the observation that the interlobular arteries
constrict when exposed to All [25, 261 and therefore may
represent important resistance vessels whose tone might be
reduced by ACE inhibition. Alternatively, wall tension might
have increased in affected vessels following drug induced vessel
relaxation and a secondary increase in internal radius. Medial
hypertrophy might also result from an effect of the altered
hormonal milieu induced by ACE inhibition on smooth muscle
cell growth and/or function. Finally, a direct vasculotoxic effect
of the drugs cannot be ruled out.
In summary, young SHR, uninephrectomized prior to the
onset of hypertension, develop significant proteinuria and mor-
phologic glomerular injury by 36 weeks of age. Micropuncture
studies in 11 week old SHR, five weeks after UNX, reveal that
overt glomerular injury is preceded by increased superficial
nephron glomerular capillary pressure, plasma flow and filtra-
tion rate. Antihypertensive therapy with the combination of
hydrochlorthiazide, hydralazine and reserpine, or ACE inhibi-
tion with either captopril or enalapril reduces kidney size and
glomerular capillary pressure and significantly lessens protein-
uric and morphologic evidence of glomerular injury in these
rats. Although systemic hypertension is prevented, ACE inhib-
itors promote hypertrophy of vascular smooth muscle in the
interlobular arteries and arterioles of the kidney, in excess of
that seen in untreated, hypertensive animals or rats treated with
the HHR combination. These findings support the hypothesis
that increased glomerular capillary hydraulic pressure and/or
kidney hypertrophy predispose to glomerular injury in models
of systemic hypertension and reduced renal mass. Ace inhibi-
tors augment renal vascular abnormalities in SHR by a mech-
anism not dependent on the presence of systemic hypertension.
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Appendix
angiotensin I converting enzyme
mean femoral artery pressure, mm Hg
protein concentration, g/lOO ml
captopril
enalapril
glomerular filtration rate (whole kidney), mI/mm
blood hematocrit in femoral artery, vol/l00 ml
HHR hydrochlorthiazide, hydralazine and reserpine
Kf glomerular capillary ultrafiltration coefficient,
ni/s . mm Hg
P hydraulic pressure, mm Hg
glomerular transcapillary hydraulic pressure
difference, GC — T, mm Hg
colloid osmotic pressure, mm Hg
arteriolar plasma flow, nllmin
renal plasma flow (whole kidney), mI/mm
resistance to blood flow, dyne. s cm5
systolic blood pressure, mm Hg
spontaneously hypertensive rat
single nephron filtration fraction
single nephron glomerular filtration rate, nI/mm
unilateral nephrectomy
Superscript
(overbar) mean value
Subscripts
A afferent arteriole
E efferent arteriole
GC glomerular capillary
T proximal tubule
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